pharmanewsdaily
1509 posts
FDA greenlights Amgen’s Nplate for pediatric immune thrombocytopenia
Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune…
December 16, 2018
Did you know eyes can improve mental health
According to new study at the University of Missouri-Columbia, researchers took account of a person’s state of mind…
December 13, 2018
Oral Contraceptives may increase risk of ischemic strokes in women
Oral Contraceptives, commonly known as birth control pills are known to block blood flow to the brain which…
December 13, 2018
Fresenius Kabi launches Omegaven for pediatric patients with parenteral nutrition-associated cholestasis in US
Fresenius Kabi, a prominent German pharmaceutical company, has introduced Omegaven (fish oil triglycerides) injectable emulsion in the United…
December 10, 2018
Millendo Therapeutics finalizes merger with OvaScience, strengthens rare disease pipeline
Millendo Therapeutics has finalized its merger with OvaScience, a Massachusetts-based biotech firm specializing in female infertility treatments. The…
December 9, 2018
Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with…
December 9, 2018
Health benefits of garlic oil for skin, hair and health problems
There are many unbelievable benefits of garlic oil for skin and health. In this post, we will discuss…
December 6, 2018
New nasal spray shows promise in treating sleep apnoea
Sleep apnoea, commonly associated with snoring, is a serious health condition where the throat tissue collapses and blocks…
December 4, 2018
Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to…
December 2, 2018
Novartis secures EC approval for Gilenya in pediatric multiple sclerosis treatment
Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod),…
December 2, 2018